---

---

tags : Trodelvy    entities : Gilead sciences, inc.   

save search

---

IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
Published: 2023-12-04 (Crawled : 11:00) - prnewswire.com
IDYA | News | $37.59 1.24% 1.04% 780K |

Health Technology

| 18.84% | O: -0.09% H: 3.48% C: 2.56%
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| -13.78% | O: -0.46% H: 1.53% C: 1.36%
ide397 trodelvy bladder cancer sciences collaboration study

---

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| -11.01% | O: 0.2% H: 1.8% C: 1.62%
trodelvy breast symposium cancer

---

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-06-23 (Crawled : 14:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| -14.29% | O: 0.28% H: 0.04% C: -1.1%
trodelvy chmp breast positive cancer

---

Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| -14.05% | O: -0.09% H: 0.27% C: -0.13%
trodelvy advantage breast cancer show

---

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
Published: 2023-02-03 (Crawled : 19:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| -17.74% | O: 4.01% H: 2.73% C: -0.18%
trodelvy fda breast cancer her2 metastatic breast cancer

---

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer
Published: 2022-10-11 (Crawled : 13:20) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| 3.86% | O: 0.05% H: 2.4% C: 1.82%
trodelvy fda breast application license review cancer her2- her2 metastatic breast cancer

---

Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
Published: 2022-08-15 (Crawled : 01:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| 6.34% | O: 1.41% H: 3.83% C: 3.7%
trodelvy acquire

---

Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
Published: 2022-08-15 (Crawled : 00:00) - prnewswire.com
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| 1.12% | O: -0.08% H: 0.39% C: 0.26%
sciences trodelvy agreement

---

Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
Published: 2022-08-15 (Crawled : 16:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| 6.34% | O: 1.41% H: 3.83% C: 3.7%
cs-02 trodelvy cancer study her2- her2 metastatic breast cancer

---

Everest Medicines Announces Approval of Trodelvy® in China for Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-06-10 (Crawled : 04:00) - prnewswire.com
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| 7.48% | O: -2.99% H: 0.0% C: 0.0%
trodelvy approval china cancer breast cancer

---

Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Published: 2022-06-06 (Crawled : 15:20) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| 5.67% | O: -1.24% H: 0.71% C: -0.87%
trodelvy phase 3

---

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| Email alert Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer

---

Everest Medicines Announces First Drug Approval of Trodelvy® in Singapore for Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-02-07 (Crawled : 01:00) - prnewswire.com
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| 3.12% | O: -1.42% H: 0.0% C: 0.0%
trodelvy drug approval cancer negative breast cancer

---

Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
Published: 2021-12-10 (Crawled : 15:00) - biospace.com/
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| -4.77% | O: -0.17% H: 0.0% C: 0.0%
trodelvy cancer negative breast cancer

---

G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Published: 2021-11-29 (Crawled : 12:00) - globenewswire.com
GILD | $66.95 0.29% 0.28% 3.8M |

Health Technology

| -4.37% | O: 0.74% H: 0.0% C: 0.0%
GTHX | $4.1 -0.24% -0.24% 470K |

Health Technology

| -69.13% | O: 0.75% H: 0.82% C: -6.28%
trodelvy phase 2 trilaciclib antibody drug trial therapeutics

---

Gainers vs Losers

74%

26%

Top 10 Gainers

MTTR | News M | $4.8 175.86% 63.6% 71M |

AGBA | $2.5 100.0% 56.6% 200M |

Finance

MLEC | $2.47 76.43% 42.62% 78M |

n/a

NUWE | $0.334 29.96% 40.99% 2.5M |

Manufacturing

EDBL | News | $6.26 66.49% 40.13% 16M |

ATGL | $2.86 46.25% 32.8% 180K |

ZAPP | $0.2175 47.16% 32.05% 16M |

n/a

ONFO | $0.6088 38.68% 27.74% 7.3M |

n/a

VIVK | $1.48 38.32% 27.7% 530K |

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.7M |

---

Your saved searches

---